Low frequency nonnucleoside reverse-transcriptase inhibitor-resistant variants contribute to failure of efavirenz-containing regimens in treatment- experienced patients

Journal of Infectious Diseases

Volumn 201, Issue 5, 2010, Pages 672-680

  Halvas, Elias K ^a   Wiegand, Ann ^b   Boltz, Valerie F ^b   Kearney, Mary ^b   Nissley, Dwight ^b   Wantman, Michael ^c   Hammer, Scott M ^d   Palmer, Sarah ^b,f   Vaida, Florin ^e   Coffin, John M ^b   Mellors, John W ^a  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^b NATIONAL INSTITUTES OF HEALTH   (United States)

^c CENTER FOR BIOSTATISTICS IN AIDS RESEARCH   (United States)

^d Columbia University College of Physicians and Surgeons ^*  (United States)

^e UNIVERSITY OF CALIFORNIA   (United States)

^f KAROLINSKA INSTITUTE   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR; ADEFOVIR; DELAVIRDINE; EFAVIRENZ; NEVIRAPINE; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR; VIRUS RNA;

ALLELE; ARTICLE; GENE SEQUENCE; GENETIC VARIABILITY; GENOTYPE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; TREATMENT FAILURE; VIRUS GENE;

ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; BENZOXAZINES; DRUG RESISTANCE, VIRAL; GENETIC VARIATION; HIV INFECTIONS; HIV REVERSE TRANSCRIPTASE; HIV-1; HUMANS; MUTATION, MISSENSE; PLASMA; POLYMERASE CHAIN REACTION; SELECTION, GENETIC; SEQUENCE ANALYSIS, DNA; TREATMENT FAILURE;

EID: 76449107778     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/650542     Document Type: Article

References (36)

1. Ho DD, Neumann AV, Perelson AS, Chen W, Leonard JM, Markowitz M. Rapid turnover of plasma virions and CD4 lymphocytes in HIV- 1 infection. Nature 1995; 373:123-126.
2. Mansky L, Temin H. Lower in vivo mutation rate of human immunodeficiency virus type 1 than that predicted from the fidelity of purified reverse transcriptase. J Virol 1995; 69(8):5087-5094.
3. Coffin JM. HIV population dynamics in vivo: implications for genetic variation, pathogenesis, and therapy. Science 1995; 267:483-489.
4. Kearney M, Palmer S, Maldarelli F, et al. Frequent polymorphism at drug resistance sites in HIV-1 protease and reverse transcriptase. AIDS 2008; 22:497-501.
5. Palmer S, Boltz V, Maldarelli F, et al. Selection and persistence of nonnucleoside reverse transcriptase inhibitor-resistant HIV-1 in patients starting and stopping non-nucleoside therapy. AIDS 2006; 20(5):701-710.
6. Hirsch MS, Gunthard HF, Schapiro JM, et al. Antiretroviral drug resistance testing in adult HIV-1 infection: 2008 recommendations of an international AIDS Society-USA Panel. Clin Infect Dis 2008; 47(2): 266-285.
7. Halvas EK, Aldrovandi G, Balfe P, et al. Blinded, multicenter comparison of methods to detect a drug-resistant mutant of human immunodeficiency virus type 1 at low frequency. J Clin Microbiol 2006; 44(7):2612-2614.
8. Palmer S, Kearney M, Maldarelli F, et al. Multiple, linked human immunodeficiency virus type 1 drug resistance mutations in treatmentexperienced patients are missed by standard genotype analysis. J Clin Microbiol 2005; 43(1):406-413.
9. Simen BB, Simons JF, Hullsiek KH, et al. Low abundance drug-resistant viral variants in chronically infected HIV-infected, antiretroviral treatment- naive patients significantly impact treatment outcomes. J Infect Dis 2009; 199:693-701.
10. Johnson JA, Li JF, Wei X, et al. Minority HIV-1 drug resistance mutations are present in antiretroviral treatment-naive populations and associate with reduced treatment efficacy. PLoS Med 2008; 5(7):e158.
11. Hance AJ, Lemiale V, Izopet J, et al. Changes in human immunodeficiency virus type 1 populations after treatment interruption in patients failing antiretroviral therapy. J Virol 2001; 75(14):6410-6417.
12. Lecossier D, Shulman N, Morand-Joubert L, et al. Detection of minority populations of HIV-1 expressing the K103N resistance mutation in patients failing nevirapine. J Acquir Immune Defic Syndr 2005; 38: 37-42.
13. Hammer SM, Vaida F, Bennett KK, et al; for the AIDS Clinical Trials Group 398 Study Team. Dual vs single protease inhibitor therapy following antiretroviral treatment failure: a randomized trial. JAMA 2002; 288:169-180.
14. Mellors JW, Palmer S, Nissley D, et al; for the ACTG 398 Study Team. Low frequency NNRTI-resistant variants contribute to failure of efavirenz- containing regimens. In: Program and abstracts of the 11th Conference on Retroviruses and Opportunistic Infections. San Francisco, CA: 2004. Abstract 39.
15. Johnson VA, Brun-Vézinet F, Clotet B, Kuritzkes DR, Pillay D, Schapiro JM, Richman DD. The International AIDS Society-USA (IAS-USA) Drug Resistance Mutations Group-update of the drug resistance mutations in HIV-1: fall 2006. Top HIV Med 2006; 14(3):125-130.
16. Thompson JD, Higgins DG, Gibson TJ. CLUSTAL W: improving the sensitivity of progressive multiple sequence alignment through sequence weighting, position-specific gap penalties and weight matrix choice. Nucleic Acids Res 1994; 22(22):4673-4680.
17. Ewing B, Green P. Base-calling of automated sequencer traces using phred. II. Error probabilities. Genome Research 1998; 8:186-194. (Pubitemid 28177230)
18. Ewing B, Hillier L, Wendl MC, Green P. Base-calling of automated sequencer traces using phred. I. Accuracy assessment. Genome Research 1998; 8:175-185. (Pubitemid 28177229)
19. Chenna R, Sugawara H, Koike T, et al. Multiple sequence alignment with the Clustal series of programs. Nucleic Acids Res 2003; 31(13):3497-3500.
20. Nickerson DA, Tobe V, Taylor SL. PolyPhred: automating the detection and genotyping of single nucleotide substitutions using fluorescencebased resequencing. Nucleic Acids Res 1997; 25(14):2745-2751.
21. Liu TF, Shafer RW. Web Resources for HIV type 1 genotypic-resistance test interpretation. Clin Infect Dis 2006; 42(11):1608-1618.
22. Xia X, Xie Z. DAMBE: software package for data analysis in molecular biology and evolution. Boston, MA: Kluwer Academic Publishers, 2000: 276.
23. Kumar S, Tamura K, Jakobsen IB, Nei M. MEGA2: molecular evolutionary genetics analysis software. Bioinformatics 2001; 17(12):1244-1245.
24. Palmer S, Boltz V, Martinson N, et al. Persistence of nevirapine-resistant HIV-1 in women after single dose nevirapine for prevention of maternal to fetal transmission. Proc Natl Acad Sci USA 2006; 103(18): 7094-7099.
25. Ihaka R, Gentleman R. R: a language for data analysis and graphics. J Comput Graph Stat 1996; 5(3):299-314.
26. Mellors JW, Dutschman G, Guang-Jin IM, Tramontano E,Winkler SR, Cheng Y-C. In vitro selection and molecular characterization of human immunodeficiency virus-1 resistant to non-nucleoside inhibitors of reverse transcriptase. Mol Pharmacol 1992; 41:446-451.
27. Halvir DV, Eastman S, Gamst A, Richman DD. Nevirapine-resistant human immunodeficiency virus: kinetics of replication and estimated prevalence in untreated patients. J Virol 1996; 70(11):7894-7899.
28. Demeter LM, Shafer RW, Meehan PM, et al. Delavirdine susceptibilities and associated reverse transcriptase mutation in human immunodeficiency virus type 1 isolates from patients in a phase I/II trial of delavirdine monotherapy (ACTG 260). Antimicrob Agents Chemother 2000; 44(3): 794-797.
29. Wainberg MA. HIV resistance to nevirapine and other non-nucleoside reverse transcriptase inhibitors. J Acquir Immune Defic Syndr 2003; 34(suppl 1):S2-S7.
30. Collins JA, Gregory Thompson M, Paintsil E, Ricketts M, Gedzior J, Alexander L. Competitive fitness of nevirapine-resistant human immunodeficiency virus type 1 mutants. J Virol 2004; 78(2):603-611.
31. Bacheler L, Jeffrey S, Hanna G, et al. Genotypic correlates of phenotypic resistance to efavirenz in virus isolates from patients failing nonnucleoside reverse transcriptase inhibitor therapy. J Virol 2001; 75(11): 4999-5008.
32. Little SJ, Holte S, Routy J-P, et al. Antiretroviral-drug resistance among patients recently infected with HIV. N Engl J Med 2002; 347(6):385-394.
33. Mellors JW, Chow J. Single-dose nevirapine to prevent maternal to child transmission of HIV-1: balancing the benefits and risks. Clin Infect Dis 2009; 48:473-475.
34. Lockman S, Shapiro RL, Smeaton LM, et al. Response to antiretroviral therapy after a single, peripartum dose of nevirapine. N Engl J Med 2007; 356(2):135-147.
35. Lockman S; A5208/OCTANE Study Team. Lopinavir/ritonavir +tenofovir/ emtricitabine is superior to nevirapine + tenofovir/emtricitabine for women with prior exposure to single-dose nevirapine: A5208 (OCTANE). In: Program and abstracts of the 16th Conference on Retroviruses and Opportunistic Infections. San Francisco, CA: February 2009. Abstract 94LB.
36. Coovadia A, Hunt G, Abrams EJ, et al. Persistent minority K103N mutations among women exposed to single-dose nevirapine and virologic response to nonnucleoside reverse-transcriptase inhibitor-based therapy. Clin Infect Dis 2009; 48:462-472.